Projects per year
Abstract
The possibility of using gene therapy for the treatment of cancer is limited by the lack of safe, intravenously administered delivery systems able to selectively deliver therapeutic genes to tumors. In this study, we investigated if the conjugation of the polypropylenimine dendrimer to lactoferrin and lactoferricin, whose receptors are overexpressed on cancer cells, could result in a selective gene delivery to tumors and a subsequently enhanced therapeutic efficacy.
The conjugation of lactoferrin and lactoferricin to the dendrimer significantly increased the gene expression in the tumor while decreasing the non-specific gene expression in the liver. Consequently, the intravenous administration of the targeted dendriplexes encoding TNFα led to the complete suppression of 60% of A431 tumors and up to 50% of B16-F10 tumors over one month. The treatment was well tolerated by the animals. These results suggest that these novel lactoferrin- and lactoferricin-bearing dendrimers are promising gene delivery systems for cancer therapy.
The conjugation of lactoferrin and lactoferricin to the dendrimer significantly increased the gene expression in the tumor while decreasing the non-specific gene expression in the liver. Consequently, the intravenous administration of the targeted dendriplexes encoding TNFα led to the complete suppression of 60% of A431 tumors and up to 50% of B16-F10 tumors over one month. The treatment was well tolerated by the animals. These results suggest that these novel lactoferrin- and lactoferricin-bearing dendrimers are promising gene delivery systems for cancer therapy.
Original language | English |
---|---|
Pages (from-to) | 1445-1454 |
Number of pages | 10 |
Journal | Nanomedicine: Nanotechnology, Biology and Medicine |
Volume | 11 |
Issue number | 6 |
Early online date | 29 Apr 2015 |
DOIs | |
Publication status | Published - 31 Aug 2015 |
Keywords
- cancer therapy
- gene delivery
- endrimer
- lactoferricin
- lactoferrin
Fingerprint
Dive into the research topics of 'Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes'. Together they form a unique fingerprint.Profiles
Projects
- 1 Finished
-
Development of tumour-targeted gene delivery systems for intravenous cancer therapy
MRC (Medical Research Council)
1/06/12 → 31/05/15
Project: Research